07.31.07
Robert M. Haggerty has been appointed to the newly created position of vice president of quality, Hyaluron Contract Manufacturing (HCM). Mr. Haggerty will be responsible for overseeing quality and regulatory compliance at the company’s Burlington, MA facility.
“Mr. Haggerty’s extensive experience will enhance our ability to provide our clients with the best possible products and services,” Shawn Kinney, president of HCM explained. “We are especially pleased with his knowledge of global quality practices as our business continues to grow both in the U.S. and abroad.”
Mr. Haggerty has more than thirty years of experience in quality and regulatory compliance in the pharmaceutical/biopharmaceutical industries. Most recently, he was the director of quality assurance at Alexion Pharmaceuticals where he was responsible for all quality assurance start-up activities at its new biotech facility. Prior to that, he held positions of increasing responsibility at Ben Venue, Dupont Merck, and Transkaryotic Therapies (now Shire). Throughout his career, Mr. Haggerty has been involved in the successful launch of multiple drug products and has achieved numerous NDA and sNDA approvals.
As vice president of quality, Mr. Haggerty will oversee the quality of products and services, as well as on-time delivery and courteous, professional communication. He will also be responsible for overseeing compliance with FDA and ISO regulations, as well as facilities and engineering validations.
“Mr. Haggerty’s extensive experience will enhance our ability to provide our clients with the best possible products and services,” Shawn Kinney, president of HCM explained. “We are especially pleased with his knowledge of global quality practices as our business continues to grow both in the U.S. and abroad.”
Mr. Haggerty has more than thirty years of experience in quality and regulatory compliance in the pharmaceutical/biopharmaceutical industries. Most recently, he was the director of quality assurance at Alexion Pharmaceuticals where he was responsible for all quality assurance start-up activities at its new biotech facility. Prior to that, he held positions of increasing responsibility at Ben Venue, Dupont Merck, and Transkaryotic Therapies (now Shire). Throughout his career, Mr. Haggerty has been involved in the successful launch of multiple drug products and has achieved numerous NDA and sNDA approvals.
As vice president of quality, Mr. Haggerty will oversee the quality of products and services, as well as on-time delivery and courteous, professional communication. He will also be responsible for overseeing compliance with FDA and ISO regulations, as well as facilities and engineering validations.